Login to Your Account

Should I Stay or Should I Go?

Experts Debate if M&A is Exit or Financing Strategy

By Trista Morrison
Staff Writer

Thursday, November 3, 2011

SAN DIEGO – Given the steep decline in third quarter biotech fundraising – down 48 percent from the same period last year – it's no surprise that companies are looking for alternatives. And at the recent Foley & Lardner Life Sciences conference in San Diego, a panel debated the merits of considering mergers and acquisitions as a financing strategy rather than an exit strategy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription